Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/phase-ii-study-of-pemetrexed-plus-gemcitabine-in-advanced-pancreatic-ruu9hd2oWD
References (28)
-
A. Adjei, C. Erlichman, J. Sloan, J. Reid, H. Pitot, R. Goldberg, P. Peethambaram, P. Atherton, L. Hanson, S. Alberts, J. Jett (2000)
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 8
-
Malcolm, J. Moore, John Andersen, Mark Green, M. Rothenberg, M. Modiano, M. Cripps, Russell, K. Portenoy, A. Storniolo, Peter Tarassoff, Robert Nelson, F. Dorr, C. Stephens, Daniel, D., Von Hoff (1997)
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 6
-
V. Heinemann (2000)
Gemcitabine: Progress in the Treatment of Pancreatic CancerOncology, 60
-
R. Schultz, M. Rothenberg, M. Koury (2000)
Sequence dependence using combinations of ALIMTA (pemetrexed disodium, LY231514, MTA), gemcitabine and oxaliplatin in human colorectal carcinoma cell lines [abstract no. 503]Clin Cancer Res, 6
-
E. Casper, M. Green, D. Kelsen, R. Heelan, T. Brown, C. Flombaum, B. Trochanowski, P. Tarassoff (2004)
Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 12
-
S. Green, G. Weiss (1992)
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 10
-
B. Fishman, Sara Pasternak, S. Wallenstein, R. Houde, J. Holland, K. Foley (1987)
The memorial pain assessment card. A valid instrument for the evaluation of cancer painCancer, 60
-
D. Rinaldi, J. Kuhn, H. Burris, F. Dorr, G. Rodriguez, S. Eckhardt, Suzanne Jones, J. Woodworth, S. Baker, C. Langley, D. Mascorro, T. Abrahams, D. Hoff (1999)
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationCancer Chemotherapy and Pharmacology, 44
-
L. Shargel, A. Yu (1980)
Applied biopharmaceutics and pharmacokinetics -
J. Tonkinson, J. Worzalla, C. Teng, L. Mendelsohn (1999)
Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.Cancer research, 59 15
-
T. Fleming (1982)
One-sample multiple testing procedure for phase II clinical trials.Biometrics, 38 1
-
C. Shih, V. Chen, L. Gossett, S. Gates, C. MackellarWarren, L. Habeck, Katherine Shackelford, L. Mendelsohn, D. Soose, V. Patel, S. Andis, J. Bewley, E. Rayl, B. Moroson, G. Beardsley, W. Kohler, M. Ratnam, R. Schultz (1997)
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.Cancer research, 57 6
-
N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffié, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza, P. Paoletti (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
-
A. Storniolo, N. Enas, Cheryl Brown, M. Voi, M. Rothenberg, R. Schilsky (1999)
An investigational new drug treatment program for patients with gemcitabineCancer, 85
-
J. Berlin, P. Catalano, James Thomas, J. Kugler, D. Haller, A. Benson (2002)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 15
-
M. Tempero, W. Plunkett, V. Ruizvan Haperen (1999)
Randomized phase II trial of dose intense gemcitabine by standard infusion vs fixed dose rate in metastatic pancreatic adenocarcinoma [abstract]Proc Am Soc Clin Oncol, 18
-
C. Niyikiza, S. Baker, D. Seitz, J. Walling, K. Nelson, J. Rusthoven, S. Stabler, P. Paoletti, A. Calvert, R. Allen (2002)
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.Molecular cancer therapeutics, 1 7
-
D. Coffey (2002)
Understanding the Cancer Biology Universe: Enigmas, Context and Future ProspectsCancer Biology & Therapy, 1
-
E.L. Kaplan, P. Meier (1958)
Nonparametric estimation of incomplete observationsJASA, 53
-
A. Jemal, Taylor Murray, Elizabeth Ward, A. Samuels, R. Tiwari, Asma Ghafoor, E. Feuer, M. Thun (2005)
Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 55
-
L. Mendelsohn, Chuan Shih, V. Chen, L. Habeck, S. Gates, K. Shackelford (1999)
Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.Seminars in oncology, 26 2 Suppl 6
-
J. Worzalla, C. Shih, R. Schultz (1998)
Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.Anticancer research, 18 5A
-
A. Tesei, L. Ricotti, F. Paola, D. Amadori, G. Frassineti, W. Zoli (2002)
In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 1
-
C. Britten, E. Izbicka, S. Hilsenbeck, R. Lawrence, K. Davidson, C. Cerna, L. Gomez, E. Rowinsky, S. Weitman, D. Hoff (1999)
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assayCancer Chemotherapy and Pharmacology, 44
-
S. Williamson, J. Crowley, R. Livingston, A. Hantel, J. Doroshow (1992)
Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lungInvestigational New Drugs, 10
-
K. Miller, J. Picus, C. Blanke, W. John, J. Clark, L. Shulman, D. Thornton, E. Rowinsky, P. Loehrer (2000)
Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 11 1
-
J. Kroep, H. Pinedo, C. Groeningen, G. Peters (1999)
Experimental drugs and drug combinations in pancreatic cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 10 Suppl 4
-
I. Firth, J. Buchanan (1973)
The wolf in the celloJournal of the Acoustical Society of America, 53
- Publisher
- Springer Journals
- Copyright
- Copyright © 2005 by Adis Data Information BV
- Subject
- Pharmacy; Pharmacy
- ISSN
- 1175-6357
- DOI
- 10.2165/00024669-200504030-00005
- Publisher site
- See Article on Publisher Site
Abstract
Background:Gemcitabine is the standard chemotherapy for the treatment of advanced pancreatic cancer. The novel multitargeted antifolate pemetrexed (Alimta®) has also demonstrated activity in this disease. These two drugs are synergistic in vitro, and a phase I study has demonstrated activity of single-agent pemetrexed in pancreatic cancer.
Journal
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012